- Home
- INCY vs NVT Comparison
INCY vs NVT Comparison
Compare INCY & NVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- NVT
- Stock Information
- Founded
- INCY 1991
- NVT 1903
- Country
- INCY United States
- NVT United Kingdom
- Employees
- INCY N/A
- NVT N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- NVT Industrial Machinery/Components
- Sector
- INCY Health Care
- NVT Industrials
- Exchange
- INCY Nasdaq
- NVT Nasdaq
- Market Cap
- INCY 13.4B
- NVT 11.1B
- IPO Year
- INCY 1993
- NVT N/A
- Fundamental
- Price
- INCY $58.98
- NVT $61.49
- Analyst Decision
- INCY Hold
- NVT Strong Buy
- Analyst Count
- INCY 20
- NVT 9
- Target Price
- INCY $73.06
- NVT $69.89
- AVG Volume (30 Days)
- INCY 1.8M
- NVT 2.2M
- Earning Date
- INCY 04-29-2025
- NVT 05-02-2025
- Dividend Yield
- INCY N/A
- NVT 1.30%
- EPS Growth
- INCY N/A
- NVT 1.65
- EPS
- INCY 0.10
- NVT 3.49
- Revenue
- INCY $4,413,226,000.00
- NVT $3,083,300,000.00
- Revenue This Year
- INCY $12.28
- NVT $9.28
- Revenue Next Year
- INCY $9.20
- NVT $5.14
- P/E Ratio
- INCY $611.49
- NVT $17.62
- Revenue Growth
- INCY 17.13
- NVT 15.90
- 52 Week Low
- INCY $52.81
- NVT $41.71
- 52 Week High
- INCY $83.95
- NVT $86.57
- Technical
- Relative Strength Index (RSI)
- INCY 44.09
- NVT 67.84
- Support Level
- INCY $57.77
- NVT $53.03
- Resistance Level
- INCY $62.87
- NVT $61.64
- Average True Range (ATR)
- INCY 1.78
- NVT 1.86
- MACD
- INCY 0.20
- NVT 1.05
- Stochastic Oscillator
- INCY 36.23
- NVT 98.04
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About NVT nVent Electric plc
nVent is a leading global provider of electrical connection and protection solutions that touches a broad range of end markets including infrastructure, industrial, commercial, and residential. NVent designs, manufacturers, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.